Cargando…
Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?
Facioscapulohumeral dystrophy (FSHD, OMIM: 158900, 158901) is the most common dystrophy in adults and so far, there is no treatment. Different loci of the disease have been characterized and they all lead to the aberrant expression of the DUX4 protein, which impairs the function of the muscle, ultim...
Autores principales: | Joubert, Romains, Mariot, Virginie, Charpentier, Marine, Concordet, Jean Paul, Dumonceaux, Julie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822190/ https://www.ncbi.nlm.nih.gov/pubmed/33374516 http://dx.doi.org/10.3390/jpm11010007 |
Ejemplares similares
-
Therapeutic Strategies Targeting DUX4 in FSHD
por: Le Gall, Laura, et al.
Publicado: (2020) -
DUX4 Expression in FSHD Muscles: Focus on Its mRNA Regulation
por: Sidlauskaite, Eva, et al.
Publicado: (2020) -
Targeting the Polyadenylation Signal of Pre-mRNA: A New Gene Silencing Approach for Facioscapulohumeral Dystrophy
por: Marsollier, Anne-Charlotte, et al.
Publicado: (2018) -
A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2020) -
RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy
por: Mariot, Virginie, et al.
Publicado: (2021)